FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release. Avtozma (tocilizumab-anoh, Celltrion) is approved for the treatment of multiple autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, and both polyarticular and systemic forms of